Literature DB >> 1498525

Epidemiology considerations in peptic ulcer disease.

P K Schlesinger1, B Robinson, T J Layden.   

Abstract

Peptic ulcer disease is a common clinical problem. The lifetime risk of peptic ulcer disease is at least 10%. Millions of Americans are affected each year, imposing a major economic burden on the health care system. The overall hospitalization and mortality rates for peptic ulcer disease seem to have decreased substantially over the past few decades. There is much to suggest, however, that these changes were occurring even before effective medical therapy became available. In addition, other influences, such as increasing age of the population at risk, changes in smoking prevalence, and increasing use of nonsteroidal anti-inflammatory drugs, have impacted on the changing epidemiology of peptic ulcer disease. Hospitalization rates for patients with complications of peptic ulcer disease have remained relatively stable or, especially in the case of elderly women with gastric ulcers, increased significantly in recent years. Understanding the epidemiology of peptic ulcer disease will allow improved assessment of the effects of medical and surgical therapy and, hopefully, provide better clues to the etiology of this diverse group of diseases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1498525

Source DB:  PubMed          Journal:  J Assoc Acad Minor Phys        ISSN: 1048-9886


  3 in total

Review 1.  Formulary management of antiulcer drugs: clinical considerations.

Authors:  S L Sankey; L S Friedman
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

Review 2.  Formulary management of antiulcer drugs: economic considerations.

Authors:  P P Tucker; D B Nash
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

3.  Impact of PSCA variation on gastric ulcer susceptibility.

Authors:  Chizu Tanikawa; Keitaro Matsuo; Michiaki Kubo; Atsushi Takahashi; Hidemi Ito; Hideo Tanaka; Yasushi Yatabe; Kenji Yamao; Naoyuki Kamatani; Kazuo Tajima; Yusuke Nakamura; Koichi Matsuda
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.